iSRS 2025 Presentation Links

To view presentations from iSRS 2025, simply select the hyperlinked session titles below. These recordings are an exclusive benefit for SRS members, so we kindly ask that you do not share this link externally.

Please note that some sessions were not recorded due to their highly interactive nature but we’re thrilled to share the many scientific insights, discussions, and breakthroughs that were captured during the event. Enjoy revisiting the energy and innovation of iSRS 2025!

You can use the public program to easily search for specific presentations and posters, click below to view.

iSRS 2025 Presymposium Workshop 1

  • Presymposium 1: Alpha Emitters for the Curious and Cautious: Everything You Want to Know About Them but Are Afraid to Ask

  • This workshop reviewed the production and available sites supplying radionuclides for Targeted Radionuclide Therapy (TAT), focusing on actinium-225, lead-212/bismuth-212, and astatine-211. It also covered the practical aspects of handling and using TAT radionuclides for radiopharmaceuticals, including radiolabeling, quality control, and necessary equipment and lab setup. The workshop targeted researchers and trainees interested in working with TAT radionuclides in their centers.

    Agenda:

    • Alpha atlas (constraints of producers of alpha emitters, map of producers, various countries and region specifics and limitations, industry); Dr. Marianna Tosato (Italy)(30 min)
    • Tips and tricks for the handling and application of TAT radionuclides (labeling strategies, QC and stability, contamination); Dr. Janke Kleynhans (Belgium)(30 minutes)
    • Round table expert discussion on the advantages and challenges of various TAT radionuclides and Q&A; Panel members: Dr. Andrew Burgoyne (USA), Dr. Jean-François Gestin (France) Dr. Valery Radchenko (Canada) (30 minutes)

iSRS 2025 Presymposium Workshop 2

  • Presymposium 2: Radiopharmaceuticals: From Bench to Bedside

  • This workshop offered an in-depth look at the journey of radiopharmaceuticals from research to clinical use. Participants learned about the latest advancements, regulatory issues, and the steps needed to turn lab discoveries into effective patient care tools. Experts from around the world presented case studies on clinical translation, addressing region-specific challenges like regulatory approval and resource availability. They shared their experiences and strategies, providing a comprehensive view of global radiopharmaceutical development. The session concluded with a round table discussion, offering ample opportunity for questions. Participants gained knowledge about global challenges and strategies in radiopharmaceutical development, equipping them to contribute effectively to the field.

    Agenda:

    • The clinical translation process in the United States: [Gallium-68]Gozetotide from an academic perspective - Dr. Giuseppe Carlucci (USA) (15 minutes)
    • PET imaging of glutamine metabolism - Dr. Hank Kung (China/USA) (15 min)
    • Beyond ‘the bedside’ - considerations for viable development of radiopharmaceuticals beyond first-in-human - Dr. Michael Wheatcroft (Australia) (15 minutes)
    • Is there a route toward green radiochemistry? - Dr. Verena Pichler (Austria) (15 minutes)
    • Q&A + Round table expert discussion with panel members Dr. Giuseppe Carlucci (USA), Dr. Hank Kung (China/USA), Dr. Verena Pichler (Austria), Dr. Federica Pisaneschi (USA), Dr. Peter Scott (USA), and Dr. Michael Wheatcroft (Australia), (30 minutes)

iSRS 2025 Presymposium Workshop 3

  • This interactive workshop was organized in collaboration between the SRS-TT and the Industry Engagement Board (IEB) and featured multiple rotating stations designed to prepare attendees for careers in industry. During the event, participants moved through a series of stations that each focused on a key aspect of professional development. Station 1 covered strategies for writing a successful resume and cover letter, while Station 2 offered guidance on how to prepare for interviews. Station 3 introduced participants to a variety of career opportunities in industry, and Station 4 highlighted valuable skills essential for industry roles. Finally, Station 5 focused on the art of networking. As this workshop was highly interactive and participants moved between stations throughout the session, no audio recording is available.

iSRS 2025 Welcome to Country

  • Welcome to Country

iSRS 2025 Keynote 1

  • Keynote 1, Cathy Cutler: Isotope Production How Far We Have Come, Current Status of Isotope Supply and What Is Needed to Ensure Supply

iSRS 2025 Opening Ceremony

  • Opening Ceremony

iSRS 2025 Keynote 2

  • Keynote 2, Maria Kavallaris: Engineering Childhood Cancer on a Tiny Scale for Precision Medicine

iSRS 2025 Scientific Session 1: Theranostics

  • (O-01) Preclinical Evaluation of 203Pb- and 212Pb-labeled mcp-PSMA Ligands for Radionuclide Theranostics of Prostate Cancer 
  • (O-02) Synthesis and radiolabeling of 203Pb-LLP2A Analogues as Potential Theranostic Agents for Melanoma
  • (O-03) Selective CXCR4-Targeting Antagonists Derived from LY2510924: [¹⁸F]AlF-NOTA-SC, [¹⁷⁷Lu]Lu-BL02, and [¹⁶¹Tb]Tb-BL02 as a Promising Trio for Precision Imaging and Therapy
  • (O-04) Synthesis and Evaluation of theranostic mono- and bivalent UniCAR T – bombesin peptide conjugates in Prostate Cancer

iSRS 2025 Scientific Session 2: Neuroscience

  • (O-05)  Development of New Albumin-binding Radiotracers for PET Imag- ing of Cerebrospinal Fluid Flow in the Glymphatic System
  • (O-06)  Development and Validation of Blood-Brain Barrier-Penetrating Bispecific Antibodies for Brain ImmunoPET in Alzheimer's Disease and Glioblastoma.
  • (O-07)  Modulating Alzheimer’s Pathology with Transthyretin Stabilizers: PET Imaging Insights
  • (O-08)  Pretargeted PET with blood-brain barrier permeable antibodies for improved Alzheimer's Disease diagnosis
  • (O-09)  A Pilot PET Imaging Study of Microtubule Dynamics in Older Adults with Cognitive Impairment
  • (O-10)  Imaging TREM2 by immunoPET

iSRS 2025 Scientific Session 3: Oncology 1

  • (O-11) HtdPP-01 and HtdPP-02: two novel GRPR/FAP heterodimeric theranostics for breast cancer
  • (O-12) Synthesis and Evaluation of [18F]Mefuparib and Its Analogues for PARP-targeted Cancer Imaging 
  • (O-13) Optimizing FAP Radiopharmaceuticals: Key Insights from a Dose Escalation Study 
  • (O-14) Applications of FcRn Inhibitors to Antibody-Based Radiopharmaceuticals 
  • (O-15) Imaging the FGFR3-S249C Oncogenic Mutation with Covalent Antibody Fragments in Preclinical Urothelial Carcinoma Models 
  • (O-16) Challenges in pretargeted imaging of programmed cell death ligand 1 (PD-L1) in syngeneic murine models: in vitro studies with a gallium-68-labeled tris(hydroxypyridinone)-tetrazine (THP-Tz) tracer

iSRS 2025 Scientific Session 4: Other Fields

  • (O-17) Cyclotron-Produced [51Mn]MnCl2 PET/MR Detects Surgically Induced Neuropathic Pain in Rats 
  • (O-18) Feasibility test of a Fluorine-18 Labeled Radioligand as an Estrogen-Related Receptor Gamma (ERRγ) targeted PET Imaging Agent 
  • (O-19) Evaluation of Antibody-based TREM2 PET in mice: Contrasting Image-Derived Blood Normalization with the Standard %ID Normalization Method 
  • (O-20) ATP Synthase is a Promising Target for Non-Invasive Imaging of Activated and Non-activated Adipose Tissues   
  • (O-21) Evaluating mRNA delivery using nuclear medicine 

iSRS 2025 Rapid-Fire Posters: Session 1

  • (RF-01) Scope and mechanistic insights of a one-pot base-free Suzuki cross-coupling approach to access [methyl- 11C]toluene derivatives from [11C]methyl iodide
  • (RF-02) Production of 77Br using the GE PETtrace Solid Target Platform
  • (RF-03) PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-differentiated Prostate Cancer (NEPC)
  • (RF-04) Separation and quantitative analysis of Th-228 in Pb-212 solution
  • (RF-05) Novel chelators for radiolanthanum coordination chemistry
  • (RF-06) Development of 11C-Phenethylamine Analogues as novel PET Tracers for the Imaging of 5-HT2A Receptor Biased Agonism
  • (RF-07) Sulfur(VI)-fluoride (SuFEx) radiolabeled substrates for site-specific enzymatic radiofluorination of biomacromolecules using pentamutant S. aureus SrtA
  • (RF-08) 73/75Se-Labeling by preparation of Se-N-bonded 1,2,5-selendiazoles
  • (RF-09) Exploring Novel Copper(II) Bispidine Chelators: Modulation of Pharmacological Properties for Improved Radiopharmaceutical Approaches
  • (RF-10) Design and Preclinical Evaluation of 68Ga-Labeled Covalently Modified Nectin-4 Targeting Peptide as a Potential Tumor Radiotracer

iSRS 2025 Keynote 3

  • Keynote 3, Matthias Herth: The Tetrazine Ligation - Bridging Pretargeting and Click Labeling in Radiochemistry

iSRS 2025 Scientific Session 5: Flourine 1

  • (O-22) Exploring ethyl- and propylpinacol-based arylboronic acid esters as stable precursors for copper-mediated radiohalogenation
  • (O-23) Preparation of aliphatic sulfamoyl [18F]fluorides ([18F]ASAFs) using the "minimalist green" approach
  • (O-24) Iron-Catalyzed Aminoradiofluorination of Alkenes to Unprotected β-Radiofluoroamines
  • (O-25) Bioorthogonal radiolabeling of GABAAR α1 subunit-specific antibody fragment for PET imaging

iSRS 2025 Scientific Session 6: Radiometals

  • (O-26) Development of four new diaza macrocycles with regioisomeric diazine carboxylic acid sidearms for stable complexation of lanthanum-133, actinium-225 and lead-203/-212 with focus on barium-131 and radium-223/-224
  • (O-27) Large Chelators for Large Radiometals: Endeavors to Complex Radium-223 and Barium-131 to Advance Targeted Alpha Therapy and Theranostics of Cancer
  • (O-28) Towards radiolabeling using metallic astatine-211: evaluation of ligands for complexation of At+
  • (O-29) Bifunctional Chelators for Cu-64/Pb-212 Theranostic Applications
  • (O-30) Development of Versatile Chelators for the Advancement of Diagnostic and Therapeutic Radiopharmaceuticals
  • (O-31) Visualizing Tumor Senescence with a Self-Immolating 64Cu-Labelled α-Fucosidase Substrate